Enlaza Therapeutics raised $100 million to develop permanently binding antibody-drug conjugates for cancer with a goal of bringing them into the first-ever human studies.
The company announced Tuesday that the Series A round was led by JP Morgan’s Life Sciences Private Capital, which was formed in late 2022 to invest…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
